Nadia Daizadeh

Also affiliated with Novartis (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis”.

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

The Journal of Allergy and Clinical Immunology In Practice(2022)10.1016/j.jaip.2022.05.019

N/A

6.6DataRank · unranked

233 citations

Amy D. Klion, Pierluigi Paggiaro, Parameswaran Nair, D. Staumont‐Sallé, Amr Radwan +12 more

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00124-7

N/A

4.3DataRank · unranked

143 citations

Sally E. Wenzel, Thomas B. Casale, J. Mark FitzGerald, Megan S. Rice, Nadia Daizadeh +8 more

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma

The Journal of Allergy and Clinical Immunology In Practice(2022)10.1016/j.jaip.2022.11.043

N/A

3.0DataRank · unranked

91 citations

Yamo Deniz, Jonathan Corren, Thomas B. Casale, J Mark FitzGerald, Kenji Izuhara +10 more

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

European Respiratory Journal(2021)10.1183/13993003.04605-2020

N/A

1.4DataRank · unranked

29 citations

Pierluigi Paggiaro, Xavier Muñoz, Thomas B. Casale, Mario Castro, Giorgio Walter Canonica +6 more

Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype

The Journal of Allergy and Clinical Immunology In Practice(2022)10.1016/j.jaip.2022.06.036

N/A

1.2DataRank · unranked

24 citations

J. Mark FitzGerald, Eric D. Bateman, Mario Castro, Ian Pavord, Jorge Máspero +8 more

Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose

The Journal of Allergy and Clinical Immunology In Practice(2022)10.1016/j.jaip.2022.03.020

N/A

0.659DataRank · unranked

17 citations

Jorge Máspero, Mario Castro, Nicola A. Hanania, Linda B. Ford, David Halpin +10 more

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma

Allergy(2022)10.1111/all.15456

N/A

0.644DataRank · unranked

8 citations

Jonathan Corren, Mario Castro, Christian Domingo, Linda Rogers, Kenneth R. Chapman +9 more

Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction

Annals of Allergy Asthma & Immunology(2022)10.1016/j.anai.2022.10.018

N/A

0DataRank · unranked

16 citations

Mario Castro, Eric D. Bateman, Ian Pavord, Alberto Papi, J. Mark FitzGerald +15 more

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Journal of Asthma and Allergy(2022)10.2147/jaa.s354013

N/A

0DataRank · unranked

1 citations

Jorge Máspero, David Halpin, David J. Jackson, Reynold A. Panettieri, Mario Castro +9 more